KRYS vs MRK

Krystal Biotech maintains a strong '10x potential' trajectory as of 2026-02-20. Vyjuvek's continued robust commercial performance in DEB provides a solid financial base and validates the company's execution capabilities. The proprietary STAR-D platform, particularly the AATD program, continues to show accelerated progress, with pivotal clinical readouts anticipated to significantly expand the Tota...

Merck & Co. is a global pharmaceutical giant with a robust oncology franchise led by Keytruda and a promising pipeline. However, for a company of its formidable size ($270B+ market cap), achieving 10x growth (~900% increase) within a 3-5 year timeframe is fundamentally improbable. The pharmaceutical industry, while innovative, is mature and highly regulated, leading to incremental rather than expo...